Bergstrand H, Andersson I, Pauwels R, Bazin H
Int Arch Allergy Appl Immunol. 1985;78(2):118-31. doi: 10.1159/000233874.
The present study examines the influence of Freund's complete adjuvant (FCA) injections on sensitized PVG rats with respect to serum levels of IgE and IgG2 alpha antibodies and total IgE (all assessed by radioimmunoassays) and the capacity of serosal mast cells to release histamine on challenge in vitro with 'immunological' secretagogues (specific antigen, anti-IgE, concanavalin A) or with compound 48/80. The rats were immunized with 10 micrograms ovalbumin (OA); alum, Bordetella pertussis vaccine, or silica gel were employed as adjuvants. Treatment with FCA was performed by single intraperitoneal injections 3, 2, or 1 week(s) before or 1 or 2 weeks after sensitization. Tests were conducted 3 weeks after sensitization. The results show that the effect of FCA treatment varied reproducibly with the adjuvant employed for sensitization and with the timing of the FCA administration. FCA treatment could either increase, fail to affect, or decrease total serum IgE and OA-IgG2 alpha antibody levels as well as serosal mast cell responsiveness, whereas OA-IgE antibody responses were decreased or not affected. Moreover, serum levels of OA-IgE and OA-IgG2 alpha antibodies and total IgE were affected by FCA treatment independently of each other. Finally, serosal mast cell responsiveness to a given secretagogue could be influenced by the FCA treatment apparently independently of that to other secretagogues. A salient finding was that effects of FCA treatment on mast cell responsiveness did not necessarily conform to effects on antibody synthesis. Collectively, these data support the opinion that the mechanisms of action of the IgE-promoting adjuvants employed differ and suggest that the expression of serosal mast cell responsiveness to each examined secretagogue can be regulated separately. They also suggest that the serosal mast cell sensitizing capacity of homocytotropic antibodies may not be adequately quantified by immunochemical methods employing reagents prepared against IgE and IgG2 alpha protein.
本研究考察了弗氏完全佐剂（FCA）注射对致敏PVG大鼠血清IgE和IgG2α抗体水平以及总IgE（均通过放射免疫测定法评估）的影响，以及浆膜肥大细胞在体外用“免疫”促分泌剂（特异性抗原、抗IgE、伴刀豆球蛋白A）或化合物48/80激发时释放组胺的能力。大鼠用10微克卵清蛋白（OA）免疫；使用明矾、百日咳博德特氏菌疫苗或硅胶作为佐剂。在致敏前3周、2周或1周或致敏后1周或2周通过单次腹腔注射进行FCA处理。在致敏3周后进行测试。结果表明，FCA处理的效果随致敏所用佐剂以及FCA给药时间的不同而可重复地变化。FCA处理可增加、不影响或降低血清总IgE和OA-IgG2α抗体水平以及浆膜肥大细胞反应性，而OA-IgE抗体反应则降低或不受影响。此外，FCA处理对OA-IgE和OA-IgG2α抗体水平以及总IgE的血清水平的影响相互独立。最后，FCA处理对浆膜肥大细胞对给定促分泌剂的反应性的影响显然独立于对其他促分泌剂的影响。一个显著的发现是，FCA处理对肥大细胞反应性的影响不一定与对抗体合成的影响一致。总体而言，这些数据支持这样一种观点，即所使用的促进IgE产生的佐剂的作用机制不同，并表明浆膜肥大细胞对每种检测的促分泌剂的反应性表达可以分别调节。它们还表明，同种嗜细胞抗体的浆膜肥大细胞致敏能力可能无法通过使用针对IgE和IgG2α蛋白制备的试剂的免疫化学方法进行充分量化。
